InvestorsHub Logo
Followers 27
Posts 744
Boards Moderated 0
Alias Born 07/12/2012

Re: geocappy1 post# 268894

Sunday, 07/24/2016 1:19:23 PM

Sunday, July 24, 2016 1:19:23 PM

Post# of 346050
Geo, you are correct; the field is moving that fast


Opdivo has dislodged Yervoy in melanoma, but the concept remains the same - COMBINE upstream and downstream inhibitors for an I/O 2.0 approach.

AZN and the other big players clearly see the future in combination therapy. Durvalumab and Bavi, in my view, will lead this development of I/O 2.0

We have to realize how fast the field is accelerating. We have a lot of posters here still focusing about Bavi's status in the I/O 1.0 solo paradigm, without considering the great combinations coming in I/O 2.0

Regards,

Joe

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News